Save this page
Save this page

My Saved Pages

  • Saved page.

My Saved Courses

  • Saved page.
Reset

Recently visited

  • Saved page.

Professor William Harnett

Strathclyde Institute of Pharmacy and Biomedical Sciences

Personal statement

I joined the Department of Immunology at Strathclyde University as a lecturer in 1991 and was appointed Professor of Molecular Immunology in 2002. Immunology was one of five University departments, which merged to form Strathclyde Institute of Pharmacy and Biomedical Sciences (SIPBS) in 2006. I acted as Director of Research in SIPBS from August 2009 until the end of 2013 and was previously Head of The immunology Department during the academic year, 2005-6.

My research interests lie in elucidating the molecular mechanisms by which parasitic worms modulate the host immune system. A particular focus is on ES-62, an anti-inflammatory molecule secreted by the filarial nematode Acanthocheilonema viteae, which we are currently exploiting with a view to developing novel drugs for allergic and autoimmune diseases. This interest in immunology and parasitology also extends to my areas of teaching.

Publications

Can parasitic worms cure the modern world's ills?
Harnett Margaret M., Harnett William
Trends in Parasitology, (2017)
http://dx.doi.org/10.1016/j.pt.2017.05.007
Dendritic cells provide a therapeutic target for synthetic small molecule analogues of the parasitic worm product, ES-62
Lumb Felicity E., Doonan James, Bell Kara S., Pineda Miguel A., Corbet Marlene, Suckling Colin J., Harnett Margaret M., Harnett William
Scientific Reports, (2017)
http://dx.doi.org/10.1038/s41598-017-01651-1
From Christian de Duve to Yoshinori Ohsumi : more to autophagy than just dining at home
Harnett Margaret M., Pineda Miguel , Latré de Laté Perle, Eason Russell J., Besteiro Sébastien, Harnett William, Langsley Gordon
Biomedical Journal Vol 40, pp. 9-22, (2017)
http://dx.doi.org/10.1016/j.bj.2016.12.004
Apicomplexan autophagy and modulation of autophagy in parasite-infected host cells
Laté de Laté Perle, Pineda Miguel, Harnett Margaret, Harnett William, Besteiro Sébastien, Langsley Gordon
Biomedical Journal Vol 40, pp. 23-30, (2017)
http://dx.doi.org/10.1016/j.bj.2017.01.001
Parasite excretory-secretory products and their effects on metabolic syndrome
Crowe Jenny, Lumb Felicity E., Harnett Margaret M., Harnett William
Parasite Immunology, (2017)
http://dx.doi.org/10.1111/pim.12410
The helminth product, ES-62 modulates dendritic cell responses by inducing the selective autophagolysosomal degradation of TLR-transducers, as exemplified by PKCδ
Eason Russell J., Bell Kara S., Marshall Fraser A. , Rodgers David T., Pineda Miguel A., Steiger Christina N., Al-Riyami Lamyaa, Harnett William, Harnett Margaret M.
Scientific Reports Vol 6, (2016)
http://dx.doi.org/10.1038/srep37276

more publications

Professional activities

Molecular and Cellular Biology of Helminth Parasites IX
Chair
30/8/2015
Molecular and Cellular Biology of Helminth Parasites IX
Speaker
30/8/2015
The parasitic worm product ES-62: a starting point for novel anti-inflammatory drug development
Invited speaker
25/8/2015
Infection and Immunity (Journal)
Editorial board member
1/1/2015
International Filariasis Meeting
Chair
26/9/2014
International Filariasis Meeting
Invited speaker
26/9/2014

more professional activities

Projects

Capacity Building Award in Integretive Mammalian Biology: A joint initiative from Glasgow University and Strathclyde University | Allan, Debbie
Jiang, Hui-Rong (Principal Investigator) Harnett, William (Co-investigator) Allan, Debbie (Research Co-investigator)
Period 01-Aug-2010 - 23-Feb-2015
BBSRC Doctoral Training Grant (DTG) | Lumb, Felicity Elspeth
Harnett, William (Principal Investigator) Rotondo, D (Co-investigator) Lumb, Felicity Elspeth (Research Co-investigator)
Period 01-Oct-2011 - 23-Feb-2016
MIMIC - Do parasitic worms and their secreted immunomudulators protect against musculosketal disease by impacting on the host microbiome?
Harnett, William (Principal Investigator) Hoskisson, Paul (Co-investigator)
Period 01-Oct-2015 - 31-Dec-2017
Can studying the mechanism of action of the parasitic worm-derived immunomodulator ES-62, inform on how to slow ageing and improve healthspan?
Harnett, William (Principal Investigator)
"The introduction of vaccines and drugs to control disease, in combination with greater access to food and improved sanitation, means that people are now living much longer. Currently this increase is staggering, equating to an extra 2.5 years of life per decade. However, improved life expectancy itself amounts to a huge new problem, in that it is not being accompanied by a similar increase in health and wellbeing. This reflects both that like a mechanical machine such as a car engine, the ageing process is naturally associated with a loss of function of its systems due to wear and tear, but also that improved wealth has resulted in a modern Western life-style, incorporating a high fat diet (HFD) that contributes to age-associated ailments such as type-2 diabetes (T2D), stroke and heart disease. This impact of increased lifespan presenting with associated ill-health has enormous socio-economic implications due to its increasingly global scale, arguing for a need to better understand the process of ageing in the context of health. Approximately one quarter of the world's population is infected with parasitic worms. Of interest, several recent reports indicate that such infections offer protection against development of conditions such as obesity, cardiovascular disease and T2D in mouse models and that similar protection may also be seen in humans. We have been studying one individual parasitic worm component - ES-62, isolated from the secretory products of the filarial nematode, Acanthocheilonema viteae, and consistent with these studies, ES-62 is highly effective in reducing the cardiovascular disease that arises in a highly susceptible strain of mouse, particularly in response to a high fat diet. Moreover, we have some preliminary data showing that ES-62 may offer some protection against development of the obesity that is associated with development of T2D. Our studies to date with ES-62 also show it to be effective in inhibiting the development of disease in mouse models of allergy, rheumatoid arthritis and systemic lupus erythematosus. What all of these diseases have in common with cardiovascular disease and T2D is the increasing realization that they are associated with unwanted inflammation. This immediately offers an explanation for ES-62's protective effects, as the parasitic worm-derived molecule possesses a range of anti-inflammatory properties. Furthermore, as ageing is also now being considered as a biological problem in the setting of chronic low-grade inflammation, this raises the possibility of investigating the effect of ES-62 on the ageing process and late-life health and well being (healthspan). Thus, we specifically plan to determine whether ES-62 can slow ageing and improve healthspan using a paradigm where mice will be fed on a high fat diet +/- ES-62. We will use this model to assess the effect of ES-62 treatment on ageing in the context of promotion of gene signatures and signalling pathways known to be associated with ageing/inflammation versus those associated with longevity and healthspan. In addition to enabling us to establish whether ES-62's anti-inflammatory properties are impacting on the ageing process at the molecular level as predicted, this strategy might allow us to validate novel biomarkers for ageing and even potential sites of therapeutic intervention. With respect to the latter, we have produced synthetic drug-like small molecule analogues (SMAs) of ES-62 during our work on the allergy and autoimmunity models, with a view to using these as a starting point in novel drug development for these conditions. Thus, although the current application is designed to increase understanding of the biology of ageing rather than drug development, we will conduct a small trial with one of these SMAs towards the final year of the project with a view to submitting future grant applications for impact funding for their development as potential therapies."
Period 01-Feb-2016 - 31-Jan-2019
Exploiting the host-parasite relationship to develop novel safe anti-inflammatory therapies
Harnett, William (Principal Investigator)
Period 01-Oct-2008 - 30-Sep-2011
Application of a parasitic helminth product to the understanding and treatment of asthma
Harnett, William (Principal Investigator)
Period 01-Jul-2009 - 30-Sep-2014

more projects

Address

Strathclyde Institute of Pharmacy and Biomedical Sciences
Hamnett Wing John Arbuthnott Building

Location Map

View University of Strathclyde in a larger map